Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

Reports of itraconazole resistance in Aspergillus fumigatus have been more frequent since
the millennium. Identifying azole resistance is critically method dependent; nevertheless …

Azoles are the mainstay of oral therapy for aspergillosis. Azole resistance in Aspergillus has
been reported infrequently. The first resistant isolate was detected in 1999 in Manchester …

Abstract Background. In March 2002, a patient in Tel Aviv, Israel, died of endocarditis
caused by Phialemonium curvatum. As part of his therapy for erectile dysfunction, the patient …

Objectives Resistance to azole antifungal drugs in Aspergillus fumigatus is now a major
clinical problem in some locations. Here we update our previous experience with data from …

Azole resistance in Aspergillus spp. is unusual. We report a patient who received long-term
treatment with itraconazole and voriconazole for bilateral chronic cavitary aspergillosis with …

Voriconazole is a new antifungal agent effective in the treatment of invasive aspergillosis.
Interpatient variation in plasma concentrations is considerable—more than 100-fold. We …

We explored concentration-toxicity relationships for itraconazole among 216 patients.
Logistic regression revealed a progressive increase in the probability of toxicity with …

Aspergillus niger is a common clinical isolate. Multiple species comprise the Aspergillus
section Nigri and are separable using sequence data. The antifungal susceptibility of these …

Background. Posaconazole is a triazole with anti-Aspergillus activity. However, little is
known about the utility of posaconazole as primary therapy for invasive pulmonary …